Antiandrogens
What happened, proxalutamide? New antiandrogen for COVID-19 is entangled in clinical data irregularities and human rights violations
Disclaimer: I am not a medical professional and this is not medical advice. From the outset of the COVID-19 pandemic,…
Denmark population-wide study confirms association between cyproterone acetate and meningioma risk – and recent users of CPA are disproportionately trans women
Previously: Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women (June 2021) Disclaimer:…
Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women
Previously: Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects…
Study of entire French population offers further data on cyproterone acetate and meningioma risk
Previously: Cyproterone acetate and meningioma risk in trans women (March 2018) Update on case reports: Cyproterone acetate and meningioma in…
Proxalutamide, a new antiandrogen, improves COVID-19 outcomes in trials of men and women
Previously: COVID-19 updates: From spironolactone to estrogen to GnRH antagonists (May 2020) Disclaimer: I am not a medical professional and…